Pfizer/Napp consider £600m UK cancer fund option after NICE process
This article was originally published in Scrip
Executive Summary
Two pharmaceutical firms, Pfizer (Wyeth) and Napp Pharmaceuticals, have decided not to submit any evidence to the UK National Institute for health and Clinical Excellence (NICE) for their respective anticancer drugs leaving the institute to terminate these appraisals and advising NHS bodies to make local decisions for their funding. This will bring the number of such terminations to eight.